Frontiers in Microbiology (Feb 2022)
Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
- Shurong Qin,
- Shurong Qin,
- Shurong Qin,
- Shurong Qin,
- Xiao Hu,
- Xiao Hu,
- Xiao Hu,
- Xiao Hu,
- Shimin Lin,
- Shimin Lin,
- Shimin Lin,
- Ji Xiao,
- Ji Xiao,
- Ji Xiao,
- Zhaoyang Wang,
- Zhaoyang Wang,
- Zhaoyang Wang,
- Jiaoyan Jia,
- Jiaoyan Jia,
- Jiaoyan Jia,
- Xiaowei Song,
- Xiaowei Song,
- Xiaowei Song,
- Kaisheng Liu,
- Zhe Ren,
- Zhe Ren,
- Zhe Ren,
- Yifei Wang,
- Yifei Wang,
- Yifei Wang
Affiliations
- Shurong Qin
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Shurong Qin
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Shurong Qin
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Shurong Qin
- College of Pharmacy, Jinan University, Guangzhou, China
- Xiao Hu
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Xiao Hu
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Xiao Hu
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Xiao Hu
- College of Pharmacy, Jinan University, Guangzhou, China
- Shimin Lin
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Shimin Lin
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Shimin Lin
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Ji Xiao
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Ji Xiao
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Ji Xiao
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Zhaoyang Wang
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Zhaoyang Wang
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Zhaoyang Wang
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Jiaoyan Jia
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Jiaoyan Jia
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Jiaoyan Jia
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Xiaowei Song
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Xiaowei Song
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Xiaowei Song
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Kaisheng Liu
- Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China
- Zhe Ren
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Zhe Ren
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Zhe Ren
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- Yifei Wang
- Guangzhou Jinan Biomedical Research and Development Center, College of Life Science and Technology, Institute of Biomedicine, Jinan University, Guangzhou, China
- Yifei Wang
- Key Laboratory of Virology of Guangzhou, Jinan University, Guangzhou, China
- Yifei Wang
- Key Laboratory of Bioengineering Medicine of Guangdong Province, Jinan University, Guangzhou, China
- DOI
- https://doi.org/10.3389/fmicb.2021.797279
- Journal volume & issue
-
Vol. 12
Abstract
Herpes simplex virus type I (HSV-1) is a member of the Alphaherpesvirinae family, which could initiate labial herpes caused by the reactivation of HSV-1 primary infection, and secondary infection even causes herpes encephalitis. The study presented here demonstrates that Hsp90 inhibitors (AT-533 and 17-AAG) directly targeted the HSV-1 UL42-Hsp90 complex, and Hsp90 interacted with HSV-1 UL42 in silicon and experiment. Interestingly, Hsp90 inhibitors also reduced virus titers of ACV-resistant clinical HSV-1 strains (153 and blue strain), revealing that HSV-1 UL42 would be a new target against ACV-resistant HSV-1 strains. Altogether, this present study indicates that Hsp90 inhibitors prevent HSV-1 proliferation by regulating the interaction between Hsp90 and HSV-1 UL42, suggesting a promising target for anti-HSV-1 therapies in the replication.
Keywords
